Cargando…

Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients

Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) can induce long-term remissions in patients with chronic lymphocytic leukemia. Treatment efficacy with Bruton's tyrosine kinase inhibitors was found similar to FCR in untreated chronic lymphocytic leukemia patients with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bloehdorn, Johannes, Krzykalla, Julia, Holzmann, Karlheinz, Gerhardinger, Andreas, Jebaraj, Billy Michael Chelliah, Bahlo, Jasmin, Humphrey, Kathryn, Tausch, Eugen, Robrecht, Sandra, Mertens, Daniel, Schneider, Christof, Fischer, Kirsten, Hallek, Michael, Döhner, Hartmut, Benner, Axel, Stilgenbauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883563/ https://www.ncbi.nlm.nih.gov/pubmed/33730841 http://dx.doi.org/10.3324/haematol.2020.251561

Ejemplares similares

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
por: Bloehdorn, Johannes, et al.
Publicado: (2021)

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription
por: Edelmann, Jennifer, et al.
Publicado: (2020)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
por: Zapatka, Marc, et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

P614: NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS
por: Qi, Jialei, et al.
Publicado: (2023)

DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy
por: Yosifov, Deyan Yordanov, et al.
Publicado: (2020)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Lamin B1 regulates somatic mutations and progression of B-cell malignancies
por: Klymenko, T, et al.
Publicado: (2018)

Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
por: Cramer, Paula, et al.
Publicado: (2020)

Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1
por: Tausch, Eugen, et al.
Publicado: (2020)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
por: Rusyn, Lisa, et al.
Publicado: (2022)

P417: GENOMIC LANDSCAPE AND PROGNOSIS IN OLDER ACUTE MYELOID LEUKEMIA PATIENTS NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY
por: Jahn, Ekaterina, et al.
Publicado: (2023)

U-RT1 – A new model for Richter transformation
por: Schmid, Teresa, et al.
Publicado: (2020)

Rare Germline Variants in ATM Are Associated with Chronic Lymphocytic Leukemia
por: Tiao, Grace, et al.
Publicado: (2017)

Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Correction: Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients
por: Jahn, Ekaterina, et al.
Publicado: (2023)

Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
por: Herling, Carmen D., et al.
Publicado: (2020)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
por: Kutsch, Nadine, et al.
Publicado: (2020)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
por: Teich, Katrin, et al.
Publicado: (2021)

Trial Watch: Lenalidomide-based immunochemotherapy
por: Semeraro, Michaela, et al.
Publicado: (2013)

Immunochemotherapy for Richter syndrome: current insights
por: Puła, Bartosz, et al.
Publicado: (2019)

Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
por: Yadagiri, Ganesh, et al.
Publicado: (2023)

Bifidobacterium in anticancer immunochemotherapy: friend or foe?
por: Procaccianti, Giorgia, et al.
Publicado: (2023)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic Leukemia
por: Göbel, Maria, et al.
Publicado: (2013)

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis
por: Schilhabel, Anke, et al.
Publicado: (2022)

Telomere shortening leads to an acceleration of synucleinopathy and impaired microglia response in a genetic mouse model
por: Scheffold, Annika, et al.
Publicado: (2016)

COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma
por: Gaitzsch, Erik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_de39nhhfq83o4k3rouj7ba5r2r